Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
Rani Therapeutics reported positive initial Phase 1a data for RT-114, an oral GLP-1/GLP-2 agonist for obesity, achieving systemic exposure greater than 150% compared to a matched 12mg subcutaneous dose. Safety and tolerability were favorable, with no serious adverse events attributed to the RaniPill capsule and only mild, transient treatment-related events consistent with the drug class.
Key figures
- Drug Name
- RT-114
- Phase Of Trial
- Phase 1a
- Dose mg
- 12
- Bioavailability
- >150% relative to matched 12mg subcutaneous dose
- Volunteers initial
- 30
- Half life oral days
- 5.6
- Volunteers expansion
- 15
- Half life subcutaneous days
- 5.3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.